// App-Quantinova.ai

SAT0330 (2018) : Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis

Researchers

Presenter

  • G. Burmester

Principal Investigators

  • W.F.C. Rigby

  • E. Choy

  • P. Nash

  • K. Winthrop

  • P.J. Mease

  • P. Young

  • T. Hendrikx

  • C. Wang

  • S. Menon

  • D. Graham

Medical Centers

  • Charite-University Medicine Berlin, Berlin, Germany

  • Geisel School of Medcn At Dartmouth, Lebanon, NH

  • Cardiff University School of Medicine, Cardiff, United Kingdom

  • The University of Queensland, Brisbane, Australia

  • Oregon Health and Science University, Portland, OR

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Pfizer Inc, Collegeville, PA

  • Pfizer Inc, Groton, CT, USA,

Locations

  • Germany

  • United States

  • United Kingdom

  • Australia

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Lymphocyte count

Drug/Treatment

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Active Comparator

  • Controlled

Phase

  • III

Study Id's

  • NCT01877668]

  • NCT01882439]

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved